We believe that collaboration is a highly effective way to advance any treatment paradigm. We are excited to pursue collaboration opportunities, including the development of novel applications of our technology platform, RTGel reverse-thermal hydrogel, within urology, uro-oncology, and other therapeutic areas.

Are you interested in collaborating with UroGen?
Contact us

Current development collaborations

UroGen has an exclusive worldwide license agreement with Allergan to evaluate a proprietary, RTGel-based formulation of BOTOX® (onabotulinumtoxinA).

The BOTOX/RTGel formulation is currently undergoing
 phase 2 clinical study for the treatment of overactive bladder.

Learn more about this collaboration >

BOTOX is a registered trademark of Allergan plc.

In April 2019, UroGen entered into an agreement with Janssen Pharmaceuticals to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest.

UroGen and Janssen will each conduct certain activities under the terms of the agreement.